<?xml version="1.0"?>
<feed xmlns="http://www.w3.org/2005/Atom" xml:lang="uk">
		<id>http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=6_Significant_Elements_Intended_For_ISRIB</id>
		<title>6 Significant Elements Intended For ISRIB - Історія редагувань</title>
		<link rel="self" type="application/atom+xml" href="http://istoriya.soippo.edu.ua/index.php?action=history&amp;feed=atom&amp;title=6_Significant_Elements_Intended_For_ISRIB"/>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=6_Significant_Elements_Intended_For_ISRIB&amp;action=history"/>
		<updated>2026-05-06T18:21:32Z</updated>
		<subtitle>Історія редагувань цієї сторінки в вікі</subtitle>
		<generator>MediaWiki 1.24.1</generator>

	<entry>
		<id>http://istoriya.soippo.edu.ua/index.php?title=6_Significant_Elements_Intended_For_ISRIB&amp;diff=161349&amp;oldid=prev</id>
		<title>Camel2park: Створена сторінка: Moreover, these programmes increase HRQoL. FRITH P1, WARK P2, LINDSTROM S3, THOMPSON P4 1Department of Respiratory Medicine, 2Respiratory Medicine, 3Respiratory...</title>
		<link rel="alternate" type="text/html" href="http://istoriya.soippo.edu.ua/index.php?title=6_Significant_Elements_Intended_For_ISRIB&amp;diff=161349&amp;oldid=prev"/>
				<updated>2017-04-05T11:42:27Z</updated>
		
		<summary type="html">&lt;p&gt;Створена сторінка: Moreover, these programmes increase HRQoL. FRITH P1, WARK P2, LINDSTROM S3, THOMPSON P4 1Department of Respiratory Medicine, 2Respiratory Medicine, 3Respiratory...&lt;/p&gt;
&lt;p&gt;&lt;b&gt;Нова сторінка&lt;/b&gt;&lt;/p&gt;&lt;div&gt;Moreover, these programmes increase HRQoL. FRITH P1, WARK P2, LINDSTROM S3, THOMPSON P4 1Department of Respiratory Medicine, 2Respiratory Medicine, 3Respiratory Medicine, 4Lung Institute of Western Australia Aim:?The MCID (minimum clinically important difference) is used to identify responders to treatment in clinical trials, enabling a comparison of responder rates between treatment arms. Relatively little is published about responder rates and their variation between trials. Method:?Data from three clinical trials with once-daily QVA149 (glycopyrronium (GLY)?+?indacaterol (IND)), GLY, IND, open-label tiotropium (TIO) and placebo (PB) was compared to examine the size of the variation in responder rates. Results:?High responder rates were seen with PB, ranging from 44.2% to 57.5% (Table). Very high TDI and SGRQ responder rates were observed with QVA149 but that study also had the highest PB responder [http://en.wikipedia.org/wiki/PSCD4 CYTH4] rate. Using TIO as an active comparator, the range of response to treatment was wide (47.3�C59.4). Spearman's rho?=?0.66 between TIO and PB suggested an association between their response rates, but the difference between TIO-PB responder rates varied in the range ?0.02 to 10.7 between outcomes and trials. Conclusion:?Placebo responder rates vary across studies. Studies in which more than half of the patients have a clinically significant [http://www.selleckchem.com/products/isrib-trans-isomer.html selleck screening library] response to placebo may be particularly [http://www.selleckchem.com/products/Metformin-hydrochloride(Glucophage).html Metformin in vitro] problematic to interpret, especially when exploring differences between treatments. Percent responders Study GLOW2 SHINE INHANCE Parameter (MCID) TDI (��1 point) SGRQ (��4 point) TDI (��1 point) SGRQ (��4 point) TDI (��1 point) SGRQ (��4 point) *p?&lt;/div&gt;</summary>
		<author><name>Camel2park</name></author>	</entry>

	</feed>